VIDEO: Single ABBV-RGX-314 treatment stabilizes diabetic retinopathy at 1 year
Click Here to Manage Email Alerts
INDIANAPOLIS — A single in-office treatment of ABBV-RGX-314 was well-tolerated and improved severity of diabetic retinopathy, according to 1-year study results presented at Academy 2024.
“A significant number of these patients had one- to two-step reversal of diabetic retinopathy severity scale,” Mohammad Rafieetary, OD, FAAO, of the Charles Retina Institute, said in this Healio video.
In the five-cohort, dose-escalating ALTITUDE study, patients with moderate to severe non-proliferative diabetic retinopathy were given a suprachoroidal injection of the investigational ABBV-RGX-314, an anti-VEGF therapy.
At year one, 33.3% of dose level 1 participants and 20.8% of dose level 2 participants achieved at least a two-step improvement in diabetic retinopathy severity score.
“This is something to look into the future, where a patient with a single genetic treatment for diabetic retinopathy can be stabilized to reduce the chance of a vision threatening episode,” Rafieetary said.
Editor’s note: This story was updated Nov. 8, 2024, to correct a spelling error in the headline. Healio regrets the error.
Collapse
Rafieetary M, et al. Suprachoroidal delivery of investigational ABBV-RGX-314 gene therapy for diabetic retinopathy: The phase 2 ALTITUDE study. Presented at: Academy 2024; Nov. 6-9; Indianapolis.
Read more about
Click Here to Manage Email Alerts